Danaher Corporation (DHR) Stock Analysis
Falling Knife setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $164.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth.
Danaher is a global science and technology company with three segments—Biotechnology, Life Sciences, and Diagnostics—serving pharmaceutical, research, hospital, and industrial customers across ~50 countries with ~60,000 employees. Approximately 59% of 2025 sales were derived... Read more
Hold if already holding. Not a fresh buy at $164.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth. Chart setup: Death cross, below all MAs, RSI 16, MACD bearish. Maintain position. Not compelling to add more. Score 5.3/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Danaher Corporation
Latest news
- Jefferies Financial Group Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price - MarketBeat — MarketBeat negative
- Sivik Global Healthcare LLC Trims Stock Holdings in Danaher Corporation $DHR - MarketBeat — MarketBeat neutral
- Evercore ISI Cuts Danaher (DHR) Price Target, Adds Shares to Tactical Outperform List - Insider Monkey — Insider Monkey positive
- Evercore ISI Cuts Danaher (DHR) Price Target, Adds Shares to Tactical Outperform List - insidermonkey.com — insidermonkey.com positive
- Evercore ISI Cuts Danaher (DHR) Price Target, Adds Shares to Tactical Outperform List - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicoutside the U.S.59%10-K Item 1A: 'In 2025 approximately 59% of our sales from continuing operations were derived from customers outside the U.S.'
- LOWGeographicChina11%10-K Item 1A: 'In 2025 we generated approximately 11% of our sales from continuing operations from China.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $164.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth. Chart setup: Death cross, below all MAs, RSI 16, MACD bearish. Maintain position. Not compelling to add more. Target $223.04 (+36.0%), stop $156.10 (−5.1%), A.R:R 7.0:1. Score 5.3/10, moderate confidence.
Take-profit target: $223.04 (+36.1% upside). Target $223.04 (+36.0%), stop $156.10 (−5.1%), A.R:R 7.0:1. Stop-loss: $156.10.
Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth; Negative momentum.
Danaher Corporation trades at a P/E of 31.8 (forward 18.0). TrendMatrix value score: 6.3/10. Verdict: Hold.
30 analysts cover DHR with a consensus score of 4.2/5. Average price target: $248.
What does Danaher Corporation do?Danaher is a global science and technology company with three segments—Biotechnology, Life Sciences, and...
Danaher is a global science and technology company with three segments—Biotechnology, Life Sciences, and Diagnostics—serving pharmaceutical, research, hospital, and industrial customers across ~50 countries with ~60,000 employees. Approximately 59% of 2025 sales were derived from outside the U.S., including ~11% from China, via a direct sales model with high recurring revenue from consumables and services.